

## S 5002

### FDA Modernization Act 2.0

**Congress:** 117 (2021–2023, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Sep 29, 2022

**Current Status:** Held at the desk.

**Latest Action:** Held at the desk. (Sep 29, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/senate-bill/5002>

## Sponsor

**Name:** Sen. Paul, Rand [R-KY]

**Party:** Republican • **State:** KY • **Chamber:** Senate

## Cosponsors (11 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Booker, Cory A. [D-NJ]	D · NJ		Sep 29, 2022
Sen. Braun, Mike [R-IN]	R · IN		Sep 29, 2022
Sen. Collins, Susan M. [R-ME]	R · ME		Sep 29, 2022
Sen. Crapo, Mike [R-ID]	R · ID		Sep 29, 2022
Sen. King, Angus S., Jr. [I-ME]	I · ME		Sep 29, 2022
Sen. Lujan, Ben Ray [D-NM]	D · NM		Sep 29, 2022
Sen. Marshall, Roger [R-KS]	R · KS		Sep 29, 2022
Sen. Padilla, Alex [D-CA]	D · CA		Sep 29, 2022
Sen. Sanders, Bernard [I-VT]	I · VT		Sep 29, 2022
Sen. Scott, Rick [R-FL]	R · FL		Sep 29, 2022
Sen. Tuberville, Tommy [R-AL]	R · AL		Sep 29, 2022

## Committee Activity

No committee referrals or activity are recorded for this bill.

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
117 S 4348	Related bill	Jul 13, 2022: Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.
117 S 4288	Related bill	May 19, 2022: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

## FDA Modernization Act 2.0

This bill authorizes the use of certain alternatives to animal testing, including cell-based assays and computer models, to obtain an exemption from the Food and Drug Administration to investigate the safety and effectiveness of a drug.

The bill also removes a requirement to use animal studies as part of the process to obtain a license for a biological product that is biosimilar or interchangeable with another biological product.

### Actions Timeline

---

- **Sep 29, 2022:** Introduced in Senate
- **Sep 29, 2022:** Passed/agreed to in Senate: Introduced in the Senate, read twice, considered, read the third time, and passed without amendment by Unanimous Consent.
- **Sep 29, 2022:** Introduced in the Senate, read twice, considered, read the third time, and passed without amendment by Unanimous Consent. (consideration: CR S5514-5515; text: CR S5514-5515)
- **Sep 29, 2022:** Message on Senate action sent to the House.
- **Sep 29, 2022:** Received in the House.
- **Sep 29, 2022:** Held at the desk.